Renovion Announces First Patient Enrolled in Phase 2 Clinical Study Evaluating ARINA-1 for the Treatment of Non-CF Bronchiectasis
Renovion and COPD Foundation Joint Release Renovion, Inc. has announced that the first patient has been enrolled in a Phase 2 clinical study evaluating ARINA-1, an investigational nebulized therapy, to treat adults with non-CF bronchiectasis (NCFBE) ( NCT05495243 ).
- Renovion and COPD Foundation Joint Release Renovion, Inc. has announced that the first patient has been enrolled in a Phase 2 clinical study evaluating ARINA-1, an investigational nebulized therapy, to treat adults with non-CF bronchiectasis (NCFBE) ( NCT05495243 ).
- The Phase 2 study is a multicenter, randomized, double-blind, placebo-controlled clinical trial.
- As a partner with Renovion through our therapeutics and digital health accelerator 360Net, were pleased to see that the ARINA-1 Phase 2 clinical study has its first patient enrolled.
- Renovion is a clinical stage pharmaceutical company focused on developing ARINA-1, novel nebulized therapy delivered to the lungs to treat pulmonary diseases.